Semaglutide should not be used to treat insulin resistance, type 1 diabetes, or ketoacidosis
Calling that simply $199 per month would understate the recurring total by at least $154 after the introductory month
This discovery has led to several GLP-1 agonists being licensed as weight loss drugs, such as Saxenda pens
So, if you don't take in enough protein, you will lose your muscle, and you won't be able to burn as many calories as you did before losing that muscle
Consistency over weeks and months matters more than perfection at every single dose
Key Educational Points: Emphasize the experimental nature No clinical trials support this combination Highlight individual compound efficacy Both peptides show strong effects as monotherapies Discuss approved alternatives CagriSema and other studied combinations offer evidence-based options Explain regulatory status Neither compound has FDA approval for metabolic applications as of 2026 Address safety concerns Overlapping side effect profiles create legitimate risks When clients express interest in research peptides, directing them toward compounds with established safety profiles and dosing protocols serves their best interests
